PMN ProMIS Neurosciences Inc.
Company Analysis
Latest News
🟢 ProMIS Neurosciences is trading 6.7% up today as it rebounds amid improving broader risk sentiment
ProMIS Neurosciences is trading at $15.00 (6.7%) up today, rebounding from recent volatility and a sharp gain on July 28 despite a lack of fresh...
🟢 ProMIS Neurosciences is trading 12.8% up today on favorable interim Phase 1b data for Alzheimer’s drug PMN310
ProMIS Neurosciences is trading 12.8% up now at $12.88 after releasing favorable six-month interim data from its PRECISE-AD Phase 1b trial of Alzheimer’s drug...
ProMIS Neurosciences Reports Favorable Interim Phase 1b Data for Alzheimer's Drug PMN310
ProMIS Neurosciences announced positive blinded six-month interim safety and biomarker data from its PRECISE-AD Phase 1b clinical trial evaluating PMN310 in...
🟢 ProMIS Neurosciences is trading 15.8% up today after bullish analyst coverage and upcoming webinar on clinical trial data
• Chardan initiated coverage with a Buy rating and a $20 price target on July 27, sparking investor interest. • The company is also set to host a webinar...
ProMIS Neurosciences Surges 12.7% on Chardan's Buy Call — But Can a Micro-Cap Biotech With No Revenue Justify a $20 Target?
Shares of ProMIS Neurosciences jumped 12.7% to $13.21 after Chardan initiated coverage with a Buy rating and a $20 price target, snapping a brutal five-session...
🟢 ProMIS Neurosciences is trading 12.7% up today after Chardan initiated coverage with a Buy rating and $20 price target
ProMIS Neurosciences is trading 12.7% up at $13.21 following a sharp after-hours relief bounce triggered by a Buy rating initiation from Chardan. • Chardan...
🟢 ProMIS Neurosciences is trading 9% up today in a relief bounce after Chardan initiated coverage with a Buy rating
ProMIS Neurosciences is trading at $12.78 (9% up) in after-hours trading as shares stage a relief bounce following a recent Buy rating from Chardan. - Chardan...
🔴 ProMIS Neurosciences is trading 5.7% down today despite Chardan initiating coverage with a Buy rating.
• ProMIS Neurosciences is trading at $11.50 (-5.74%) today. • Chardan initiated coverage on PMN with a "Buy" rating and a $20.00 price target, suggesting...
🔴 ProMIS Neurosciences is trading 6% down today as traders unwind recent volatility-driven gains
ProMIS Neurosciences is trading 6% down today at $11.90 as the stock undergoes a technical pullback following a sharp multi-day rebound. • The decline follows...
🟢 ProMIS Neurosciences is trading 10.1% up today in a technical rebound
ProMIS Neurosciences is trading 10.1% up at $13.88 as the stock stages a technical rebound following recent volatility. • The move reverses a significant...
🟢 ProMIS Neurosciences is trading 14.2% up today despite no clear company-specific catalyst
ProMIS Neurosciences is trading at $14.40 (+14.20%) in pre-market following a sharp overnight gap, despite a lack of company-specific news, earnings updates,...
🔴 ProMIS Neurosciences is trading 10.6% down
ProMIS Neurosciences is trading at $12.50, down 10.6% from a comparison close of $13.99 during regular trading. This is a price-action follow-up, so a separate...
🔴 ProMIS Neurosciences is trading 5.4% down today on profit-taking after last week's Alzheimer's data rally
ProMIS Neurosciences is trading 5.4% down at $14.26 today, appearing to undergo profit-taking and consolidation following a sharp multi-day rally. • The...
🟢 ProMIS Neurosciences is trading 6.6% up today on positive Alzheimer’s trial data
ProMIS Neurosciences is trading 6.6% up at $16.20 today, extending a multi-day rally following positive clinical updates for its Alzheimer’s treatment...
🟢 ProMIS Neurosciences is trading 10.4% up
ProMIS Neurosciences is trading at $14.68, up 10.4% from a comparison close of $13.30 during regular trading. This is a price-action follow-up, so a separate...
🟢 ProMIS Neurosciences is trading 5.26% up today on PMN310 clinical data momentum
ProMIS Neurosciences is trading at $14.00 (+5.26%) as investors continue to react to recent PMN310 clinical data showing the first human evidence of...
🔴 ProMIS Neurosciences is trading 5% down today on profit-taking following PMN310 clinical data updates
ProMIS Neurosciences is trading at $13.30 (5% down) as investors digest recent clinical updates and engage in profit-taking following a multi-day rally. • The...
🟢 ProMIS Neurosciences is trading 7.4% up today after presenting positive PMN310 clinical data at AAIC 2026
ProMIS Neurosciences is trading 7.4% up at $13.75 after presenting first-in-human evidence that its lead Alzheimer’s antibody, PMN310, successfully engages...
🟢 ProMIS Neurosciences is trading 12.5% up
ProMIS Neurosciences is trading at $14.40, up 12.5% from a comparison close of $12.80 during pre-market. This is a price-action follow-up, so a separate...
ProMIS Neurosciences Bounces Back on Alzheimer's Drug Momentum — But Can a $120M Biotech Survive a Giants' War?
Shares of ProMIS Neurosciences surged 7.7% in pre-market trading to $13.78, clawing back most of Friday's 10.2% drop, as investors continued to chase momentum...